Oxford BioMedica Appoints Corporate Broker

RNS Number : 4026Y
Oxford Biomedica PLC
17 May 2016

Oxford BioMedica Appoints Corporate Broker



Oxford, UK - 17 May 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, is pleased to announce that it has appointed Jefferies Hoare Govett as Sole Corporate Broker with immediate effect.




For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton


Tel: +44 (0)20 3709 5700


Jefferies Hoare Govett:

Simon Hardy

Max Jones

Chris Binks


Tel: +44 (0)20 7029 8000


Notes for editors


About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.



This information is provided by RNS
The company news service from the London Stock Exchange